Type 1 diabetes study identifies subset of patients with strong response to therapy
Sunday, August 18, 2013 - 21:30
in Health & Medicine
Primary results from a new clinical trial show that a discrete subset of patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) demonstrated especially robust response with greater preservation of C-peptide, a biomarker of islet cell function, compared to controls, suggesting that these patients could be identified prior to treatment.